Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

Kite Pharma has appointed two former Amgen directors to senior positions in its research team.

Dr William Go joins as senior director, clinical development, and Jeff Aycock joins as senior director, clinical operations. 

Dr Go was most recently US medical lead for Amgen's cancer treatments Vectibix (panitumumab) and medical director in the company's global development business. Aycock, meanwhile, was most recently director, oncology study management and US regional lead at Amgen, overseeing five oncology programmes.

The two will now add their expertise in cancer to Kite as it plans to advance its immunotherapy plans in oncology.

They are the fourth and fifth senior figures to make their way from Amgen to Kite this year, following the appointments of VP, clinical development, Dr Jeffrey Wiezorek in May and of chief medical officer Dr David Chang earlier this month to replace Dr Keith Nolop who spent just one year in the role.

Outside R&D, Kite also added Dr Rizwana Sproule from Amgen as head VP, regulatory affairs in January.

24th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics